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Abstract
Background—It remains unknown if later life breast cancer risk as determined by reproductive 
history is mediated by postmenopausal breast density and/or sex steroid levels.
Methods—Increased breast density is a strong surrogate for future breast cancer risk. A cross-
sectional study with a longitudinal follow up for breast health outcomes evaluated women without 
breast cancer (n = 1,023; 682 = parous), drawn from a high risk postmenopausal population, with 
questionnaire reported reproductive histories. The questionnaire was linked to prospective 
screening mammogram breast density measurements, and saliva biospecimens that were used to 
assess sex steroid hormone levels.
Results—Expected age and postmenopause related declines in salivary estradiol (E), 
progesterone (P), dehydroepiandrosterone (DHEA) and testosterone (T) levels were observed. 
This was most pronounced for DHEA and T, which were also the only postmenopausal hormone 
levels significantly associated with any reproductive characteristics: parity and breast feeding for 
DHEA, age-at-first birth for T. Postmenopausal breast density was borderline significantly lower 
with parity and higher body mass index (BMI). After multivariate analysis, T was the only 
hormone level to retain any association (negative, p<0.05) with breast density.
Conclusions and General Significance—While reproductive characteristics, in particular 
parity, generally demonstrated independent associations with postmenopausal breast density and 
E, P and DHEA levels, T levels showed concordant inverse associations with age-at-first birth and 
breast density. These findings suggest that reproductive effects and later life salivary sex steroid 
hormone levels may have independent effects on later life breast density and cancer risk.
Corresponding author: Rochelle Ereman, rereman@marincounty.org; phone: 415-473-3056, County of Marin, Department of Health 
and Human Services, San Rafael, CA 94903. 
HHS Public Access
Author manuscript
BBA Clin. Author manuscript; available in PMC 2016 June 01.
Published in final edited form as:














Postmenopausal Breast Cancer Risk Cohort; Reproductive History; Mammographic Density; 
Saliva Biospecimens; Salivary Sex Steroid Levels
1. Introduction
Reproductive history, and in particular age at first birth, has been repeatedly demonstrated to 
be associated with breast cancer risk (1). However, there is a lack of understanding of the 
mechanisms by which pregnancy confers changes in breast cancer risk, thus limiting the 
extent to which these findings can be translated into interventions for prevention. Two 
mechanistic hypotheses include: i. Persistent changes in the hormonal milieu, and ii. 
Permanent morphological and gene expression changes imprinted by pregnancy-induced 
mammary gland differentiation. There is support for each of these hypotheses from 
epidemiological (1,2), observation and intervention research (3), and animal studies (4–6). 
Either of these hypotheses may be manifested by changes in later life breast density.
In addition to age-at-first full-term birth, epidemiological evidence supports an association 
between breast cancer risk and prior pregnancy characteristics including pre-term birth, 
preeclampsia, multi-fetal gestation and small placental weight (1,7,8). Mammographic 
density has a strong relationship to breast cancer risk (9,10). Reproductive history has also 
been reported to be related to breast density, with increased density associated with pre-term 
birth, nulliparity, and late age-at-first birth (8, 11–14). These findings appear strongest for 
first pregnancies, although many remain controversial (10). Confirmation of these findings 
could provide evidence that pregnancy characteristics influence breast cancer risk through 
hormonally mediated changes in the structure of the breast. There is however, conflicting 
evidence for a link between pregnancy, hormone levels and breast cancer. A secondary 
analysis of the Nurses Health Study showed a relationship between postmenopausal serum 
hormone levels and parity, as well as age-at-first birth (15); but other studies have shown no 
association between circulating sex hormones and parity (16–18). In postmenopausal 
women, circulating sex steroid hormone levels are strongly associated with breast cancer 
risk (17, 18), but any association of these hormone levels with breast density remains 
uncertain.
To address the question of whether early life reproductive factors, known to be associated 
with later life breast cancer risk, either mediate or moderate postmenopausal breast density 
and/or salivary sex steroid levels, we performed a cross-sectional analysis drawn from the 
larger Marin Women’s Study (MWS). Postmenopausal women without breast cancer (n = 
1,023; 682 = parous), and their self reported lifestyle and reproductive characteristics 
(including first pregnancy events), were examined along with screening mammogram breast 
density measurements. Self obtained saliva biospecimens were used to assess sex steroid 
hormone levels (estradiol, progesterone, dehydroepiandrosterone, testosterone). Saliva 
measurements reflect (but are not necessarily equal to) free plasma or serum concentrations 
of various steroidal hormones, certain growth factors, and many drugs if they are capable of 
being transferred by either intracellular (e.g. diffusion) or extracellular (e.g. ultrafiltration) 
mechanisms. Thus, numerous studies of saliva-based diagnostics have established that 
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clinically relevant analyte concentrations in saliva correlated with tissue fluid levels and can 
be used either for drug monitoring or to evaluate endocrine function, in particular circulating 
(unbound) levels of lipid-soluble steroids like cortisol, aldosterone, dehydroepiandrosterone, 
testosterone, progesterone, and estradiol (19).
2. Materials and Methods
2.1 Marin Women’s Study (MWS) Population and Measurements
This study was conducted within the context of the MWS. Marin residents were recruited 
through mammography facilities in Marin County and San Francisco which are included in 
the San Francisco Mammography Registry (SFMR), one of seven registries comprising the 
National Cancer Institute Breast Cancer Surveillance Consortium. This study was approved 
by the Marin General Hospital and Kaiser Permanente Northern California Institutional 
Review Boards, and all participants provided informed consent to fully participate in the 
study. Primary data collection in the MWS included self-reported information via a detailed 
questionnaire and saliva samples collected from consenting women. Secondary data were 
obtained by linkage with the SFMR on volumetric compositional breast density and breast 
cancer case status, as well as family history, weight and height. The MWS has been 
previously described and characterized (12). To date, 13,365 women have been enrolled in 
the MWS and completed the questionnaire. Of these, about 85% also consented to saliva 
donation, and 70% completed the process of donation as instructed and produced biobanked 
specimens.
2.2 Questionnaire Components
The questionnaire was filled out by all consenting women as their entry point into the MWS. 
It included detailed questions about reproductive history, life course socioeconomic data, 
alcohol use, and medication use, including NSAIDs, which can affect endogenous levels of 
steroids like DHEA (20). Additional questions about well-established risk factors included 
exogenous hormone exposures, and history of previous breast procedures. Reproductive 
factors included age at menarche and menopause, and specific pregnancy-related questions 
included parity, age-at-first birth, infertility and treatment for infertility, duration of breast 
feeding, birth weight of children, preterm birth, pregnancy weight gain, and pregnancy 
related hypertension.
2.3 Calibrated Mammographic Density
One of the novel features of this study is the measure of breast density as % fibroglandular 
volume (%FGV), by the method of single-energy X-ray absorptiometry (SXA). This method 
uses a calibration phantom of the same thickness as the compressed breast, circumventing 
some of the problems associated with other breast density measures, such as subjectivity and 
a lack of absolute reference standards (21). This study used the first generation calibration 
phantom (Gamma). Initial results on over 8600 women showed that SXA is precise and 
accurate when using reference phantoms, and inversely correlated with age, BMI and 
menopausal status; it is also positively associated with breast cancer risk (22, 23). %FGV 
data were obtained from the SFMR through a cooperative agreement upon linkage to MWS 
data for all consenting women.
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2.4 Saliva collection and Steroid Hormone Assay
Saliva samples were collected to assess systemic steroid hormone levels, as saliva testing 
represents a cost effective approach to screening large populations (19). Sex steroids were 
measured from cryobanked saliva after precipitating out all cell and particulate components. 
At the time of entry into the MWS, women were asked on the questionnaire if they were 
willing to donate a saliva specimen. Those who consented were sent a kit in the mail. 
Returned specimens were bar coded, logged and cryobanked. In total, 8,598 saliva samples 
have been processed. Processed supernatants were sent to Aeron Biotechnology, Inc. (San 
Leandro, CA) for radioimmunoassay (RIA) of dehydroepiandrosterone (DHEA), estradiol 
(E), progesterone (P) and testosterone (T). The entire MWS sample set submitted for 
analysis of these four steroid hormones (n = 1,784 ) were compared to results from an 
independent contemporary cohort of female samples randomly submitted for commercial 
analysis, to confirm expected age-specific changes in the hormone levels (Figure 1). Criteria 
for inclusion in the MWS saliva analysis required submission of a non-bloody early morning 
saliva sample of > 3 ml volume, following at least eight hours of fasting. Samples from post-
menopausal women required attesting to an absence of menses for at least one year.
2.5 Statistical Analyses
The analytic sample comprised 1,023 postmenopausal women not taking exogenous 
hormones who had an analyzable saliva sample for hormone levels and questionnaire data 
on the variables included in the model. Distributions of the study variables were examined 
against a reference range of postmenopausal women to verify that levels were consistent 
with the known ranges for this population. Multivariable linear regression analyses were 
constructed using Stata 11.2 (StataCorp. 2009. Stata Statistical Software: Release 11. 
College Station, TX: StataCorp LP) to examine the associations between salivary hormone 
levels, %FGV and reproductive factors, controlling for relevant confounders. The models 
employed robust regression using iteratively reweighted least squares to minimize the 
effects of outliers. To examine the association between salivary hormone levels and known 
or suspected confounders, a separate model was constructed for each hormone and included 
a base set of confounding variables. The base set of variables included continuous current 
age, BMI, hours of weekly moderate or vigorous exercise, number of alcoholic drinks 
consumed per day, parity, and age at menopause, as well as race (Black, White, Asian, 
Hispanic, Other), education (high school or less, some college, college degree or higher), 
use of complementary and alternative medicines (CAMS – or natural nonprescription 
hormone medications) (yes/no), and age at menarche (10 or younger, 11–14, 15+). One 
model was constructed for the entire population examining the reproductive factors of 
parity, age at menarche, and age at menopause. Another model restricted to parous women 
was examined using a wider range of reproductive factors related to the first pregnancy 
including weeks gestation, high blood pressure, gestational weight gain, age-at-first full term 
birth, birth weight, and duration of breast feeding. Prior to regression, hormone levels were 
log transformed and % FGV was square root transformed to normalize the distribution. 
Women were excluded from all analyses if they had a history of breast cancer, if their first 
birth was multiple gestation, if they had used antiestrogens in the last five years, if they had 
a history of ovariectomy, or if any of the variable data was missing from the questionnaire. 
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In the model where %FGV was the dependent variable, we also controlled for family history 
of breast cancer (first degree relative), hormone use near the time of the mammogram, and a 
measure of the number of days between saliva donation and %FGV measurement. Models in 
which one of the four assayed hormone levels was the dependent variable included the base 
set of confounding variables plus batch, number of hours fasting, and time of saliva 
donation. Given the numerous comparisons being made, borderline significant findings are 
not highlighted in the results section.
3. Results
3.1 The Marin Women’s Study (MWS) biospecimens and saliva steroid levels
The results of the 1,784 saliva supernatants submitted for commercial analysis of steroid 
hormone levels are presented in Figure 1. The age specific hormone levels of the MWS 
cohort appear generally concordant with those of an independent and contemporary cohort 
of women, in which expected age and postmenopausal hormonal declines are apparent. In 
both these female cohorts, the most significant age-related hormonal decreases were noted in 
DHEA and testosterone levels (Figure 1). Many of the elevated estradiol and progesterone 
levels in MWS study subjects over age 50 illustrated in this figure reflected their reported 
use of HRT; these study samples were excluded from the subsequent analysis of 
postmenopausal subjects, resulting in a final postmenopausal set of 1,023 saliva samples for 
hormone analysis.
3.2 Postmenopausal study sample summary characteristics (breast density, reproductive 
parameters, hormone levels)
The study sample (n= 1,023) represents the subset of postmenopausal study subjects 
submitting saliva samples eligible for hormone analysis (Table 1). The mean %FGV in the 
analysis population was 28.49. The majority of the population is white, has a college degree, 
a normal BMI, and is on average 11.8 years postmenopausal.
Table 2 presents the distribution of reproductive characteristics for this postmenopausal 
MWS cohort. Nearly one quarter (24.8%) of women had a first birth at age 30 years or 
older. Pregnancy induced hypertension was reported by 4.47% of the population, and high 
and low birth weight were reported by 9.14% and 5.49% of the cohort, respectively. Ninety-
two percent (92%) of the respondents reported that their first birth was full term, with a 
mean 29.65 pound weight gain. On average, respondents reported 6.34 months of 
breastfeeding after this first birth.
The distribution of hormone levels (geometric means) are presented in Table 3. Mean levels 
for the analysis populations were within the reference range for postmenopausal women for 
DHEA, estradiol, progesterone and testosterone (109.56, 0.77, 20.32, and 19.87, 
respectively).
3.3 Multivariate analyses
A multivariate model examining the reproductive factors of parity, age at menarche and age 
at menopause is presented in Table 4. In this set of models, the only association between one 
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of the hormone levels and parity was the positive association with DHEA (p=0.01). Age was 
significantly negatively associated with levels of DHEA and testosterone (p<0.001). BMI 
was significantly associated with DHEA (p=0.002), as was weekly exercise (p=0.04) and 
current smoking (p=0.01). BMI was also significantly associated with estradiol (p=0.001). 
Use of complementary and alternative medicine (CAMS) was significantly associated with 
progesterone levels (p=0.04).
Table 5 shows associations between hormone levels and characteristics of first birth in the 
postmenopausal subset of parous women (n=682). When controlling for all other factors in 
the model, including levels of the three other study hormones, breast feeding was 
significantly positively associated with DHEA levels (p=0.04). No other reproductive 
factors were significantly related to DHEA. The proportion of the variability in DHEA 
explained by this model was 38% due in large part to the inclusion of estradiol, progesterone 
and testosterone as variables; an analogous model that did not include simultaneous control 
for the other three hormones had an R squared value of 10% (data not shown). There were 
no significant associations between reproductive factors and estradiol or progesterone. The 
model for estradiol explained 19% of the variability in estradiol. Thirty nine percent (39%) 
of the variability in testosterone was explained by this model.
The results of the multivariate regression model of hormone levels on %FGV are shown in 
Table 6. The only hormone significantly associated with %FGV was testosterone, which 
showed a negative association with %FGV (p=0.04). BMI was also significantly, negatively 
associated with %FGV (p<0.001). Asian women had significantly higher %FGV than white 
women (p=0.02) even after control for the other model variables.
4 Discussion
4.1 Parity, Postmenopausal Steroid Hormone Associations, and Breast Cancer Risk
In this study population of 1,023 postmenopausal women in the MWS, parity was positively 
associated with only DHEA. No other salivary hormones were significantly related to parity 
in this group. When these associations are taken without adjusting for other hormones, it is 
hard to determine the extent to which postmenopausal DHEA influences breast cancer risk 
in this population. Postmenopausal testosterone levels have clearly been linked to an 
increased risk of developing hormone receptor positive breast cancer (24), but such evidence 
relating to DHEA has not been as convincing. Earlier prospective case control studies have 
shown that postmenopausal DHEA levels correlate positively with breast cancer risk (25). 
However, in a more recent analysis from the Nurses’ Health Study of endogenous hormone 
levels and postmenopausal breast cancer risk wherein significantly positive associations 
with risk were shown for estradiol and testosterone levels (RR=1.3 and 1.29, respectively), 
the weakerincrease in breast cancer risk seen with sulfated DHEA (RR=1.15) became non-
significant upon stepwise regression analysis (24). As a metabolic precursor to both 
androgens and estrogens, DHEA is produced in the adrenals, gonads and brain; and even 
much later in life DHEA remains the most abundant of all circulating sex steroids, as shown 
in the current study (Table 3). Although a weak partial agonist of the androgen receptor 
(AR) and both forms of estrogen receptor (ERalpha and ERbeta), the higher circulating 
levels of DHEA over E2 and T do not come close to compensating for its much weaker AR 
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and ER binding affinities. Therefore, consistent with the current controversy over whether 
DHEA enhances or reduces the risk of breast (or prostate) cancer, not to mention the fact 
that sex steroid receptor-independent effects of DHEA have also been reported that could 
alter mammary gland susceptibility to tumorigenesis (26), it is not possible to conclude that 
our observed association between parity and DHEA is at all linked to postmenopausal breast 
cancer risk. Of note, DHEA levels can also be induced by vigorous exercise and caloric 
restriction sufficient to achieve a lean body mass.. Since vigorous exercise and low BMI are 
clearly associated with decreased postmenopausal breast cancer risk, higher DHEA levels in 
the MWS population could actually correlate with lower breast cancer risk by acting as a 
surrogate biomarker for risk-reducing exercise and lower BMI in this population.
4.2 First Pregnancy Association with Postmenopausal Hormone Levels and 
Mammographic Density
DHEA was significantly associated with breastfeeding among parous women, but among 
this group of parous women, the number of births (parity) was not significantly associated 
with DHEA. The only other association between a reproductive factor and hormone level 
among parous women was the borderline significant negative association between 
testosterone and age-at-first birth between ages 20–29 (compared to birth before age 20). 
The postmenopausal hormone levels (DHEA, testosterone) best associated with pregnancy 
characteristics did not show comparable associations with postmenopausal mammographic 
density. This observation may mean that pregnancy itself induces early, persistent, and 
protective morphologic changes in the breast reflected in postmenopausal breast density, but 
by mechanisms other than long lived hormonal changes. In this fashion, first pregnancy 
characteristics and postmenopausal hormone levels would be expected to influence breast 
cancer risk independently.
4.3 Reproductive Characteristics and Postmenopausal Mammographic Density
Given the strong association between breast cancer risk and mammographic density, 
whether measured by conventional BIRADS (Breast Imaging Reporting and Data system) 
classification or more modern SXA quantitation of %FGV (as reported here), there has been 
continuing interest in determining either correlative or causative links between 
mammographic density and breast cancer risk although, to date, such biological and genetic 
links remain largely unresolved (10). Clear associations between changes in breast density 
and increasing age, higher BMI, and exogenous hormone (e.g. combined E + P replacement 
therapy) or anti-hormone (e.g. antiestrogen) use have spurred epidemiologic studies seeking 
other associations consistent with long term breast hormonal exposure. So far, meta analyses 
of these studies indicate no consistent or significant associations between postmenopausal 
breast density and age-at-first birth, breast feeding, or other reproductive characteristics 
(after adjustment for age and BMI) other than parity (10). We observed that postmenopausal 
breast density was borderline significantly lower with parity (as well as with higher BMI), 
but not with age at menarche, first birth, or menopause. Hence, while our findings appear to 
be in complete agreement with many other epidemiologic studies, they do not implicate long 
term hormonal exposure and do not shed any additional light on the partially protective 
effect of parity on postmenopausal breast density.
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4.4 Study Strengths and Weaknesses
This study has a number of important strengths, including a relatively large sample size, a 
novel measure of breast density, and the availability of information on a wide variety of 
reproductive characteristics and other breast cancer risk factors.
The primary limitation in this study is the use of self-reported data for reproductive history 
and early life risk factors such as age at menarche. Though it is possible that women may 
not accurately recall information about their first pregnancy, particularly if it occurred in the 
distant past, we would expect that they would accurately recall the major events including 
their age when they got pregnant, and whether they breast-fed. To the extent that 
misclassification of exposures is present, we expect it would be nondifferential (i.e., not 
associated with %FGV or salivary hormone level), and would thus bias the results toward 
the null. Another limitation is that, despite the fact that the overall sample size in this study 
was large, the sample size was small for specific subgroup analyses. Studies with larger 
populations may be better able to detect significant associations between birth 
characteristics, hormone levels, and breast density where they exist. Selection bias may be 
present in the sample of patients providing saliva samples for the hormone analyses; women 
who consented to donate saliva were significantly more likely to be of White Non-Hispanic 
race and to be of higher socioeconomic status based on education and income, but were not 
significantly different in terms of family history of breast cancer or current age. This 
selective participation would only be expected to bias the results if the associations between 
birth characteristics, hormone levels, and breast density differ by race or socioeconomic 
status. While we do not anticipate that this would be the case, bias in the results due to 
selective participation cannot be ruled out. This does, however, limit the ability to generalize 
the findings here to a broader, more racially diverse population. Finally, the analyses of birth 
characteristics were intentionally restricted to first births, but it will be important to 
determine whether the findings for first birth characteristics hold for all births or whether 
they are unique to the first birth (e.g., whether total duration of breast-feeding has the same 
association with hormone levels as duration of breast-feeding after the first birth).
5. Summary and Conclusions
Expected age and postmenopause related declines in estradiol (E), progesterone (P), 
dehyroepiandrosterone (DHEA) and testosterone (T) levels were observed. DHEA and T 
were the only postmenopausal hormone levels significantly associated with any reproductive 
characteristics: parity and breast feeding for DHEA, age-at-first birth for T. Postmenopausal 
breast density was borderline significantly negatively associated with parity, and T was the 
only hormone level to retain any association with %FGV in multivariable analysis (negative, 
p=0.04). These findings suggest that first pregnancy effects on later life breast density and 
cancer risk are not strictly mediated by later life sex steroid hormone levels.
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Age-specific salivary sex steroid hormone levels in the Marin Women’s Study (MWS) 
cohort. Early morning saliva samples (n = 1,784) collected, cryobanked and processed in 
compliance with the MWS protocol, as described in Methods, were analyzed by RIA for 
levels of estradiol (E), progesterone (P), testosterone (T) and dehydroepiandrosterone 
(DHEA). The age (decade) distribution of log-transformed hormone values are box plotted 
as shown; and the age-specific sex steroid hormone levels from the MWS samples are 
shown in relation to a geographically independent, contemporary cohort of US females (not 
part of the MWS) who provided saliva samples by the same collection protocol, identically 
processed and analyzed (Aeron Biotechnology). Age-specific changes in hormone levels 
were tested for significance (p-values) by analysis of trends. A subset of these MWS saliva 
samples collected from postmenopausal women (n = 1,023) were used for the study 
comparison with reproductive characteristics and postmenopausal breast density.
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Number of alcoholic drinks per day 0.91 (.99)
BMI 24.76 (4.69)
Hours of strenuous and moderate exercise per week 8.99 (3.94)
Age of menopause (among menopausal women) 50.81 (5.74)








 HS or less 4.69%
 Some college 26.20%
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Table 2
Distribution of Reproductive Characteristics (n=1,023)
Characteristic Percent








 10 or younger 4.99%
 11–14 86.61%
 15+ 8.41%










 First Pregnancy Characteristic in Parous Women Mean (SD)
Pregnancy weight gain (pounds) 29.65 (11.70)
Months of breastfeeding (first child) 6.34 (7.03)
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Table 3
Mean levels of salivary hormones (postmenopausal women, n=1,023)
Geometric means (pg/ml) Reference range (postmenopausal women)
DHEA 109.56 33–200 (age-specific)
Estradiol 0.77 <1.5
Progesterone 20.32 <50
Testosterone 19.87 11–35 (age-specific)
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Table 4
Linear Regression Model: Salivary Hormone Levels in postmenopausal MWS women with hormone 
measurement and model variables (n=1,023)
Log DHEA
Beta coefficient (95% 
CI)
Log Estradiol
Beta coefficient (95% 
CI)
Log Progesterone
Beta coefficient (95% 
CI)
Log Testosterone
Beta coefficient (95% 
CI)
Reproductive Factors
Parity (0–5) .04 (.01, .07)* .01 (−.01, .02) −.001 (−.02, .02) .01 (−.02, .03)
Menarche (vs. ≤10)
 11–14 .07 (−.11, .26) −.0002 (−.10, .10) .07 (−.06, .20) .10 (−.04, .24)
 15+ .02 (−.06, .10) −.04 (−.17, .08) .11 (−.05, .27) .05 (−.12, .23)
Age of menopause .0004 (−.01, .01) −.001 (−.004, .003) −.002 (−.01, .003) .004 (−.002, .01)
Other Factors
Age (years) −.02 (−.03, −.02)* −.001 (−.004, .002) .001 (−.003, .004) −.01 (−.01, −.01)*
CAMS use .04 (−.16, .23) .04 (−.07, .14) .14 (.003, .28)* .05 (−.10, .20)
BMI .01 (.005, .02)* .01 (−.003, .01)* −.01 (−.01, .001) .02 (.01, .02)
Alcohol consumption .02 (−.02, .06) .01 (−.02, .03) −.03 (−.06, .002)** .03 (−.002, .06)**
Weekly exercise .01 (.001, .02)* .001 (−.004, .01) −.001 (−.01, .01) .003 (−.005, .01)
Smoking (versus never)
 Current .31 (.07, .55)* −.10 (−.23, .03) .05 (−.12, .21) .11 (−.08, .29)
 Former .02 (−.06, .10) .01 (−.03, .06) .02 (−.04, .08) .04 (−.02, .11)
Race (vs white)
 Black .09 (−.55, .73) −.22 (−.57, .12) .20 (−.25, .65) −.18 (−.67, .31)
 Asian −.10 (−.34, .15) .02 (−.12, .15) −.04 (−.22, .13) .01 (−.18, .20)
 Other −.16 (−.46, .14) −.02 (−.18, .15) .01 (−.21, .22) −.20 (−.43, .03)**
 Hispanic −.22 (−.51, .07) .01 (−.15, .16) .10 (−.11, .31) −.16 (−.38, .07)
Education (versus HS or less)
 Some college .05 (−.15, .25) .02 (−.09, .13) −.12 (−.26, .03) −.05 (−.21, .10)
 College graduate .02 (−.17, .21) .01 (−.09, .12) −.11 (−.24, .03) −.05 (−.20, .10)
R2 .09 .04 .02 .04
Controlled for batch, hours fasting, and time donated. Models do not include simultaneous control for other three hormones
**
denotes borderline significance (p<0.1)
*
denotes statistical significance (p<0.05)
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Table 5
Linear Regression Model: Salivary Hormone Levels in parous postmenopausal MWS women with hormone 
measurement and model variables (n=682)
Log DHEA
Beta coefficient (95% 
CI)
Log Estradiol
Beta coefficient (95% 
CI)
Log Progesterone
Beta coefficient (95% 
CI)
Log Testosterone
Beta coefficient (95% 
CI)
Reproductive Factors
Parity (number: 1–5) .04 (−.01, .08) .01 (−.01, .04) .00004 (−.04, .04) −.003 (−.04, .03)
Weeks gestation (versus 38+ 
weeks)
 36–37 weeks .09 (−.08, .26) −.03 (−.12, .07) −.02 (−.15, .11) −.04 (−.16, .08)
 <35 weeks .04 (−.31, .38) .04 (−.16, .24) .001 (−.27, .27) .10 (−.15, .34)
High Blood Pressure (vs. No) −.12 (−.32, .08) −.03 (−.14, .09) .10 (−.05, .26) .01 (−.13, .16)
Gestational weight gain (lbs) .0005 (−.003, .004) −.002 (−.004, .001) .001 (−.002, .004) −.0001 (−.003, .003)
Age at first birth (vs. <20)
 20–29 .14 (−.07, .36) .02 (−.11, .14) −.07 (−.23, .10) −.14 (−.29, .02)**
 30–34 .12 (−.11, .35) .02 (−.11, .16) −.07 (−.25, .11) −.09 (−.25, .07)
 35+ .12 (−.12, .37) −.01 (−.15, .13) −.05 (−.24, .14) −.08 (−.25, .10)
Birthweight (vs. normal)
 Low .09 (−.09, .28) −.03 (−.13, .08) .02 (−.13, .16) −.09 (−.23, .04)
 High .02 (−.12, .16) .02 (−.06, .11) .08 (−.03, .19) −.02 (−.12, .08)
Breastfeeding (months) .01 (.0003, .01)* .0004 (−.003, .004) −.003 (−.01, .002) −.0004 (−.005, .004)
Menarche (vs. ≤ 10)
 11–14 .01 (−.18, .20) .02 (−.09, .13) −.02 (−.17, .13) .09 (−.04, .23)
 15+ −.03 (−.27, .20) −.03 (−.17, .10) .06 (−.12, .25) .07 (−.09, .24)
Other Factors
Age (years) −.02 (−.03, −.01)* −.0004 (−.004, .003) .01 (.004, .01)* .004 (−.0005, .01)**
CAMS use −.11 (−.32, .10) −.02 (−.14, .11) .20 (.03, .36)* −.18 (−.33, −.03)*
BMI .005 (−.01, .01) .004 (−.002, .01) −.01 (−.02, −.01)* .01 (.002, .02)*
Alcohol consumption .03 (−.01, .07) −.01 (−.04, .02) −.01 (−.04, .03) .02 (−.01, .06)
Weekly exercise .01 (−.003, .02) −.002 (−.01, .004) .00003 (−.01, .01) .004 (−.004, .01)
Smoking (versus never)
 Current .23 (−.01, .47)** .04 (−.10, .18) −.21 (−.40, −.02)* −.001 (−.17, .17)
 Former −.05 (−.13, .04) .03 (−.02, .08) .01 (−.06, .08) .002 (−.06, .06)













Mockus et al. Page 17
Log DHEA
Beta coefficient (95% 
CI)
Log Estradiol
Beta coefficient (95% 
CI)
Log Progesterone
Beta coefficient (95% 
CI)
Log Testosterone
Beta coefficient (95% 
CI)
Race (vs white)
 Black .86 (−.17, 1.88) −.01 (−.61, .60) −.28 (−1.09, .53) −.41 (−1.14, .33)
 Asian −.09 (−.32, .15) −.001 (−.14, .14) .02 (−.16, .21) .0002 (−.17, .17)
 Other −.08 (−.40, .24) .04 (−.14, .23) .14 (−.11, .39) −.12 (−.34, .11)
 Hispanic −.13 (−.40, .15) .08 (−.08, .25) .21 (−.01, .42)** −.08 (−.28, .11)
Education (versus HS or less)
 Some college .05 (−.15, .24) .01 (−.10, .13) −.14 (−.29, .01)** −.03 (−.16, .11)
 College graduate .01 (−.18, .20) −.01 (−.12, .10) −.12 (−.27, .03) −.02 (−.15, .12)
R2 .38 .19 .20 .39
¶
Controlled for batch, hours fasting, and time donated. Includes simultaneous control for other hormones.
**
denotes borderline significance (p<0.1)
*
denotes statistical significance (p<0.05)













Mockus et al. Page 18
Table 6
Linear Regression Model: %FGV in parous postmenopausal women (n=636)
%FGV
Beta coefficient (95% CI)
Reproductive Factors
Parity (number: 0–5) −.07 (−.15, .01)**
Menarche (vs. ≤10)
 11–14 −.28 (−.73, .17)
 15+ −.18 (−.72, .36)
Age of menopause .01 (−.01, .02)
Salivary Hormone Levels
DHEA .08 (−.08, .24)
Estradiol .09 (−.11, .29)
Progesterone .05 (−.10, .21)
Testosterone −.24 (−.45, −.03)*
Other Factors
Age (years) −.01 (−.02, .01)
Hormone use at mammogram −.44 (−.95, .08)**
BMI −.20 (−.22, −.18)*
Race (vs white)
 Black .82 (−.52, 2.16)
 Asian .62 (.10, 1.15)*
 Other .27 (−.50, 1.05)
 Hispanic .34 (−.28, .95)
Education (versus HS or less)
 Some college −.09 (−.51, .34)
 College graduate .01 (−.39, .41)
Weekly exercise −.003 (−.03, .02)
Alcohol consumption −.01 (−.10, .09)
Smoking (versus never)
 Current −.06 (−.62, .49)
 Former .03 (−.15, .22)
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%FGV
Beta coefficient (95% CI)
First degree relative with breast cancer .09 (−.13, .30)
R2 .33
**
denotes borderline significance (p<0.1)
*
denotes statistical significance (p<0.05)
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